Questions & Answers
Neuren Pharmaceuticals is a specialty biopharmaceutical company with a focus on rare, neurodevelopmental disorders. Our lead medicine, Trofinetide showed strongly positive results in a Phase III study in Rett syndrome, meetings its co-primary endpoints and demonstrating statistically significant improvements over placebo. We now have NNZ-2591 in Phase II trials across 4 disorders, including Angelman syndrome.
Learn more about us at our website: www.neurenpharma.com.
Clinical Trials provide information to determine whether a medicine is safe and effective. Regulatory Agencies worldwide require the data from such clinical trials to assess a medicine’s benefit to the population being treated.
Clinical trials are carried out in humans after laboratory and animal testing demonstrates that a treatment is likely to be efficacious and safe. The trials move through a series of phases (I, II , III and IV), and follow protocols (approved by Ethics Committees) that balance potential risks with benefits.
All participants in this study will receive thorough study-related physical, psychological, and behavioural evaluations by a study doctor.
While there is no guaranteed benefit to participants in a clinical research study, participation may help to advance scientific knowledge in the area that is being studied.
The phases of clinical trials are the stages where researchers conduct experiments to find out if a certain medicine or intervention is considered efficacious as a new medical treatment. These range from Phase 1 to Phase 4. The image below summarises the four phases.
In Phase 2 studies like this, researchers administer the study medication to a group of patients who have the condition for which the medicine is being developed.
The next stage is Phase 3, where researchers will confirm the efficacy of the new treatment.
A protocol outlines the plan for the clinical trial. It is carefully designed to protect the wellbeing of the participants and answer specific research questions. A protocol outlines who can participate in the trial, when different assessments should be taken, which procedures will be done, details of medications and how much to give, as well as information on the duration of the study. While participating in a clinical trial, participants are seen regularly by the study team to monitor their condition and determine the safety and efficacy of the treatment.
Your child must meet the eligibility criteria detailed in the protocol. The criteria are based on age, type of condition, medical history and a range of clinical diagnostics and assessments. This is to ensure that the trial will produce useful and reliable results and contribute to the safety analysis of the study.
The clinical team at site will discuss with you to confirm whether your child is eligible to participate in this trial.
The current study for children and adolescents with Angelman syndrome is a Phase 2 trial. This trial will include up to 20 male and female participants between the ages of 3-17 years. Your participation will last for approximately 19 weeks.
The study primarily examines the safety profile of the study medication in children with Angelman syndrome. NNZ-2591 has already been tested in healthy human volunteers for 7 days (the Phase 1 study) and was shown to be generally safe and well tolerated in that study.
This Phase 2 study is intended to confirm that NNZ-2591 is a well-tolerated medicine that is worthy of further development for children and adolescents with Angelman syndrome. This study is also measuring efficacy (whether individuals see improvement or benefit from taking the study medication). It includes a number of assessments that look at a number of areas of concern in Angelman syndrome such as overall well-being, communication, behavior, and quality of life.
At this stage, our development program is focused on paediatric patients, however, we are planning an adult development program. Timings for this adult program have not yet been defined.
Blood samples will be taken by skilled study nurses who have extensive experience working with children who have neurodevelopmental disorders, specifically Angelman syndrome.
The ethical and legal codes that govern medical practice also apply to clinical research. All clinical research has built in safe guards, including independent ethics committee review and approval with built in safeguards to protect the participants’ information. The trial follows a carefully controlled protocol, a study plan which details what researchers will do throughout the study. Safety data is reviewed as a clinical trial progresses. Researchers report the results of the trial at scientific meetings, to medical journals, and to various government agencies. Individual participants' information will be de-identified to remain anonymous and will not be mentioned in any reports.
Yes, a participant can choose to withdraw from a clinical trial at any time. You should speak to the study team to let them know you no longer wish for the participant to continue in the trial.
Unfortunately, we’re unable to provide access to the study medication once your participation has ended. The medicine has not yet been studied (in either humans or animals) beyond 13 weeks of dosing, and so we would not have Ethics Committee approval to proceed beyond this timeframe.
You can participate in the study; however, this participation will obviously be subject to the relevant Covid-19 border restrictions between your state and whichever site you choose.
Flexibility has been built into the study protocol and supporting structures to allow for continued subject participation during the Covid-19 pandemic. However, to ensure the integrity of the study, there are a number of study visits where it is critical that on site attendance occur. If you live interstate, you will need to consider the effect that state-based lockdowns may have on your ability to participate and travel.
Attending the clinic for the consenting and screening visits are not reimbursable. It’s important to note that any costs incurred to attend these visits will be at cost to you. However, if your child is subsequently deemed eligible after the screening period, you may retrospectively apply for reimbursement of any out-of-pocket costs incurred during the screening phase.
Having the COVID-19 vaccine does not affect your child’s eligibility to participate in this study. Nor is it an issue if received part-way through the study. We’d advise having the vaccination ahead of participation in the trial to avoid any potential confusion over side effects. The study team will record any vaccines or medications that have been received during the treatment period.